Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientific Officer Daniel Lorrain
Contineum has streamlined its discovery programs to focus on drug candidates for the treatment of inflammatory and fibrotic diseases. These actions have resulted in a limited workforce reduction for the Company’s
Contineum is making its research team smaller so it can focus on making fewer, more important medicines for certain diseases. When a company shrinks its team, watch whether the medicines they're keeping moving forward work well—that tells you if the tough choice was smart.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.